Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition

TOKYO - Eisai registered swift benefits from its acquisition of MGI Pharma with oncology revenues accounting for 10 percent of its global sales, Eisai CEO Haruo Naito told an Oct. 31 earnings conference